Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Insulin: Biosynthesis, Chemistry, and Preparation

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biotherapeutic strategies for quorum quenching in Salmonella Typhi: a review.

Archives of microbiology·2026

Same author

Molecular docking: a computational approach for the discovery of novel targets against visceral leishmaniasis.

Journal of molecular modeling·2026

Same author

Deciphering the bioactive properties of sodium lignosulfonate (LIG) and LIG-induced cell death of human fungal pathogen <i>Candida albicans</i>.

In silico pharmacology·2025

Same author

Computational evidence of cancer and reproductive toxicological potential from short-chain PFAS exposure through network toxicology and docking approaches.

Toxicology mechanisms and methods·2025

Same author

Role of the microbiome in diabetic wound healing: implications for new therapeutic approaches.

Archives of microbiology·2025

Same author

Upcoming generation nanoengineered antimicrobial delivery system for targeting multidrug-resistant microbes.

Critical reviews in biotechnology·2025

Search research articles

Related Experiment Video

Updated: Jan 18, 2026

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

Exploring multi-functional biopolymer polyhydroxyalkanoates in diabetes treatment.

Gunjan Adwani¹, Sharda Bharti¹, Awanish Kumar¹

¹Department of Biotechnology, National Institute of Technology, Raipur, Chhattisgarh, India.

Journal of Biomaterials Science. Polymer Edition

|May 29, 2025

Summary

Polyhydroxyalkanoates (PHAs) show promise as biomaterials for diabetes management, offering controlled drug delivery and wound healing. Further research is needed to overcome production challenges and fully realize their therapeutic potential.

Keywords:

Poly(3-hydroxybutyrate)diabetes insulin delivery poly(4-hydroxybutyrate)wound healing

More Related Videos

The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications

The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications

Published on: October 7, 2016

Tracking Hypoxic Signaling within Encapsulated Cell Aggregates

Tracking Hypoxic Signaling within Encapsulated Cell Aggregates

Published on: December 16, 2011

Related Experiment Videos

Last Updated: Jan 18, 2026

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications

The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications

Published on: October 7, 2016

Tracking Hypoxic Signaling within Encapsulated Cell Aggregates

Tracking Hypoxic Signaling within Encapsulated Cell Aggregates

Published on: December 16, 2011

Area of Science:

Biomaterials Science
Polymer Chemistry
Endocrinology

Background:

Diabetes mellitus is a global chronic metabolic disorder characterized by hyperglycemia.
Current treatments for diabetes require non-invasive insulin delivery and effective wound healing therapeutics.
There is a significant need for novel biomaterials to enhance diabetes management.

Purpose of the Study:

To review the therapeutic potential of Polyhydroxyalkanoates (PHAs) in diabetes management.
To explore the application of PHAs as advanced biomaterials for antidiabetic and wound healing therapies.
To highlight the challenges and future directions for PHA utilization in diabetes care.

Main Methods:

Literature review focusing on Polyhydroxyalkanoates (PHAs) in biomedical applications.
Analysis of PHA properties including biocompatibility, biodegradability, and controlled drug release.
Examination of PHA applications in bioartificial pancreas development and wound healing.

Main Results:

PHAs exhibit biocompatibility, biodegradability, and can be synthesized into scaffolds and nanomaterials for sustained drug delivery.
PHAs demonstrate antidiabetic and antimicrobial activities, beneficial for wound healing.
PHA-based scaffolds provide a supportive environment for pancreatic cell encapsulation in bioartificial pancreas designs.

Conclusions:

PHAs offer a versatile platform for developing advanced diabetes therapeutics, including controlled insulin delivery and improved wound healing.
Challenges such as high production costs and market integration require further investigation.
Continued research is essential to fully harness the therapeutic capabilities of PHAs for comprehensive diabetes management.